PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30418757-4	2019	Here we show that, upon incorporation into short ssDNAs, the cytidine nucleoside analogue 2"-deoxyzebularine (dZ) becomes capable of inhibiting the catalytic activity of selected APOBEC variants derived from APOBEC3A, APOBEC3B, and APOBEC3G, supporting a mechanism in which ssDNA delivers dZ to the active site.	cytidine nucleoside	61-80	apolipoprotein B mRNA editing enzyme catalytic subunit 3A	Homo sapiens	208-216
32905646-1	2021	Reduced expression of the uptake transporter, OCTN1 (SLC22A4), has been reported as a strong predictor of poor event-free and overall survival in multiple cohorts of patients with acute myeloid leukemia (AML) receiving the cytidine nucleoside analog, cytarabine (Ara-C).	cytidine nucleoside	223-242	solute carrier family 22 member 4	Homo sapiens	46-51
32905646-1	2021	Reduced expression of the uptake transporter, OCTN1 (SLC22A4), has been reported as a strong predictor of poor event-free and overall survival in multiple cohorts of patients with acute myeloid leukemia (AML) receiving the cytidine nucleoside analog, cytarabine (Ara-C).	cytidine nucleoside	223-242	solute carrier family 22 member 4	Homo sapiens	53-60
30418757-4	2019	Here we show that, upon incorporation into short ssDNAs, the cytidine nucleoside analogue 2"-deoxyzebularine (dZ) becomes capable of inhibiting the catalytic activity of selected APOBEC variants derived from APOBEC3A, APOBEC3B, and APOBEC3G, supporting a mechanism in which ssDNA delivers dZ to the active site.	cytidine nucleoside	61-80	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	218-226
30418757-4	2019	Here we show that, upon incorporation into short ssDNAs, the cytidine nucleoside analogue 2"-deoxyzebularine (dZ) becomes capable of inhibiting the catalytic activity of selected APOBEC variants derived from APOBEC3A, APOBEC3B, and APOBEC3G, supporting a mechanism in which ssDNA delivers dZ to the active site.	cytidine nucleoside	61-80	apolipoprotein B mRNA editing enzyme catalytic subunit 3G	Homo sapiens	232-240
27160178-1	2016	Human cytidine deaminase (hCDA) is a biomedically important enzyme able to inactivate cytidine nucleoside analogs such as the antileukemic agent cytosine arabinoside (AraC) and thereby limit antineoplastic efficacy.	cytidine nucleoside	86-105	cytidine deaminase	Homo sapiens	6-24
28209616-3	2017	Through transcriptomic profiling, we determined that low expression of the ergothioneine transporter OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multiple cohorts of AML patients receiving treatment with the cytidine nucleoside analogue cytarabine.	cytidine nucleoside	251-270	solute carrier family 22 member 4	Homo sapiens	101-106
28209616-3	2017	Through transcriptomic profiling, we determined that low expression of the ergothioneine transporter OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multiple cohorts of AML patients receiving treatment with the cytidine nucleoside analogue cytarabine.	cytidine nucleoside	251-270	solute carrier family 22 member 4	Homo sapiens	108-115
27160178-1	2016	Human cytidine deaminase (hCDA) is a biomedically important enzyme able to inactivate cytidine nucleoside analogs such as the antileukemic agent cytosine arabinoside (AraC) and thereby limit antineoplastic efficacy.	cytidine nucleoside	86-105	cytidine deaminase	Homo sapiens	26-30
27036028-3	2016	We applied this approach to identify functional disparities between two cytidine nucleoside analogs: azacytidine (AZA) and decitabine (DAC).	cytidine nucleoside	72-91	arylacetamide deacetylase	Homo sapiens	135-138
20126405-1	2010	BACKGROUND: The cytidine nucleoside analogs azacitidine (AZA) and decitabine (DAC) are used for the treatment of patients with myelodysplastic syndromes and acute myeloid leukemia (AML).	cytidine nucleoside	16-35	arylacetamide deacetylase	Homo sapiens	78-81